Study sees shift from pharmaceuticals to biologics for generic drug makers through 2020
BURLINGTON, Mass. — Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.
The report, "Indian Generics Manufacturers Penetrate U.S. Generics Market: Case Studies in Success and Failure and Near-Term Opportunities," released Tuesday by healthcare market research firm Decision Resources, found that during that time, the loss of brand sales to generics will be more than $155 billion, with 2015 being the biggest single year for patent expiries. Through 2020, the opportunities for generic drug makers will shift increasingly from small-molecule drugs to biologics.
"Teva is the leading global generics company and provides Indian companies with a template for successful growth," Decision Resources group SVP Kate Hohenberg said. "The company’s growth has been achieved largely through acquisitions to expand its global footprint and technological capabilities."
Currently, Teva, Mylan and Actavis lead the U.S. generics industry, while Indian companies have increased their presence here, including Ranbaxy Labs, Dr. Reddy’s Labs and Lupin. However, they face such challenges as the requirement for increased spending on research and development and investment in advanced manufacturing technologies, as opportunities shift from generic pharmaceuticals to biosimilars.
Greenstone launches authorized generic voriconazole for oral suspension
PEAPACK, N.J. — Greenstone has launched a version of a drug used to treat fungal infections, the company said.
Greenstone, the generics subsidiary of Pfizer, announced the introduction of voriconazole for oral suspension, an authorized generic version of Pfizer’s Vfend. Authorized generics are branded drugs sold at a discount under their generic names.
Greenstone is selling the drug in the 40 mg-per-milliliter strength. Vfend had sales of about $17.1 million during the 12-month period that ended in June, according to IMS Health.
Novartis, Incyte drug produces higher survival rates in patients with myelofibrosis
BASEL, Switzerland — A drug marketed by Novartis and Incyte Corp. extends the lives of patients with a life-threatening blood cancer to a greater extent than conventional therapy or placebo, according to results of a late-stage clinical trial.
Novartis announced the results of two phase-3 studies of Jakavi (ruxolitinib) in patients with myelofibrosis, presenting them at the American Society of Hematology’s annual meeting and exposition in New Orleans.
Myelofibrosis is an uncommon blood cancer that causes enlargement of the spleen, scarring of the bone marow and other symptoms. According to the studies, titled "COMFORT-I" and "COMFORT-II," Jakavi may increase the probability of 10-year survival of patients with the cancer by more than 50% compared with conventional therapy. The drug is approved in the United States for patients with intermediate- or high-risk myelofibrosis and is marketed by Incyte under the name Jakafi.